

Ascension Saint Joseph

Take Home Points

- Obstructive jaundice has rarely known to cause pseudohyponatremia
- Patients with obstructive jaundice if present with asymptomatic hyponatremia especially in the setting of euvolemia which cannot be explained by other etiologies should be evaluated further.
- Measuring low density lipoproteins and serum lipids can establish pseudohyponatremia in these patients
- However, if these levels are normal, watchful waiting and close monitoring after relief of obstruction should be exercised which may spontaneously improve hyponatremia.
- Delay in relieving obstruction may worsen disease course and overall outcomes.

CONTACT

Mohammed Gandam, MD Ascension Saint Joseph Hospital drmdraasiq@gmail.com Website: <u>18478a5a?lipi=urn%3Ali%3Apage%3Ad_f</u> lagship3 profile view base contact det ails%3BTkUv9rafSZGHskvKhk60dQ%3D% <u>3D</u>

- rare.
- Case reports of pseudohyponatremia in patients with obstructive jaundice have been previously described by Sivakumar et. al and Adashek et. al.
- They described the artifactual hyponatremia in the setting of hyperlipidemia and hyper lipoproteinemia.
- We describe a case of pseudohyponatremia with obstructive jaundice with modest elevation in total cholesterol and LDL

last 6 weeks.

- and calculated was 275.
- near the head of the pancreas.
- CA 19-9 was noted to be 149.6.
- sodium improved to 132.

A Rare Case of Pseudohyponatremia in an Elderly Male with Pancreatic Adenocarcinoma – Laboratory artifact or Idiopathic?

Mohammed Gandam, MD¹; Aquila Fathima, MD¹; Aashritha Ramesh, MD¹; Alan Auerbach, MD¹; Sujatha Kailas, MD¹; George Atia, MD¹; Shyam Chalise, MD¹ ¹Ascension Saint Joseph Hospital, Chicago, IL

INTRODUCTION

• Electrolyte imbalance in patients with obstructive jaundice is

Case Description

• A 73-year-old Asian male patient with a history of type 2 diabetes mellitus presented with a 4-week history of generalized malaise, 2- week history of yellowish discoloration of both eyes, nightly upper abdominal pain, nausea and one episode of vomiting. He also reported a 10 kg weight loss in the

• He was noted to have hyponatremia and elevated liver enzymes by his primary doctor and was sent to the ER for evaluation. • His serum sodium on admission was 117. Sodium corrected to hyperglycemia was 122. Measured serum osmolality was 261

• He was treated with NS 1L over 10 hours and AM lipid panel was obtained (Table 2). A CT of the abdomen and pelvis showed a distended gallbladder with dilatation of the intrahepatic and common biliary ducts with the CBD measuring up to 11 mm

The serum sodium did not improve after IV fluid administration which were eventually stopped as he appeared to be clinically euvolemic. An ERCP revealed a 2 cm biliary/pancreatic stricture compatible with pancreatic cancer and a 7 F stent was placed.

• His serum sodium improved spontaneously without intervention. At discharge, his corrected serum

A EUS guided biopsy confirmed pancreatic adenocarcinoma.

Table 1. Chem Profile trends

Chem profile	Ref. Range	5/18/22 8:53	5/24/22 12:25	5/25/22 4:05	5/25/22 18:33	5/26/22 0:58	5/26/22 6:55	5/26/22 17:18	5/27/22 6:06	6/2/22 8:10
Total Protein	6.4 - 8.9 g/dL	7.7	6.6	6			6.8		6.8	7.2
Glucose	70 - 99 mg/dL	268	411	162	232	265	217	246	193	149
BUN	7 - 25 mg/dL	18	13	8	8	8	8	7	5	18
CREATIN INE	0.6 - 1.3 mg/dL	1.02	0.96	0.88	0.86	0.87	0.86	0.68	0.7	0.85
Sodium	133 - 144 mmol/L	124	117	119	118	119	121	121	125	128
Potassiu m	3.5 - 5.2 mmol/L	4.8	4.2	3.7	4.1	3.9	3.4	4.4	3.9	4.5
Chloride	98 - 107 mmol/L	88	81	87	86	89	89	91	92	93
CO2	21 - 31 mmol/L	27	23	25	20	23	23	21	24	27
Anion Gap	6 - 14 mmol/L	9	13	7	12	7	9	9	9	8
BUN/Cre atinine Ratio	6.0 - 20.0	17.6	13.5	9.1	9.3	9.2	9.3	10.3	7.1	21.2
Calcium	8.6 - 10.3 mg/dL	9.7	9.1	8.6	8.7	8.4	8.6	8.4	8.7	9.3
Phosphor us	2.5 - 4.5 mg/dL						2.6			
Albumin	3.5 - 5.7 g/dL	4.2	3.8	3.4			3.7		3.8	3.8
AST	13 - 39 IU/L	150	168	167			88		73	104
ALT	7 - 52 IU/L	614	448	401			346		273	385
Alkaline Phosphat ase	40 - 129 IU/L	363	589	480			514		424	524
Total Bilirubin	0.0 - 1.0 mg/dL	15.8	27.2	25.4			14.9		10.5	5.7

Table 2. Lipid Profile

Lipid profile	Ref. Range	5/24/22 12:25
Cholesterol	Latest Ref Range: 0 - 200 mg/dL	349
Triglycerides	Latest Ref Range: 0 - 150 mg/dL	180
HDL	Latest Ref Range: 35 - 55 mg/dL	13
Non-HDL Cholesterol	Latest Units: mg/dL	336
Chol/HDL Ratio	Latest Ref Range: 2.00 - 5.50	26.8
VLDL	Latest Ref Range: 2.0 - 50.0 mg/dL	36
LDL Calculated	Latest Ref Range: <130 mg/dL	300

- 921-2.

DISCUSSION

• Unmeasured proteins and/or lipids may be seen in intra-and extra hepatic cholestasis which can falsely result in a low serum sodium. These have been reported in a few case reports which demonstrated the laboratory abnormality accounting for unmeasured serum lipids and/or proteins.

• These spurious anomalies may impede diagnosis and initial management and may worsen the clinical course.

• However, our case demonstrates pseudohyponatremia in the absence of these laboratory abnormalities.

• It is unknown as to why and how obstructive jaundice contributes to pseudohyponatremia.

• A high degree of caution should be exercised when met with conflicting clinical and laboratory abnormalities.

• Clinicians may exercise inappropriate choice of fluids especially when met with those suffering from pancreatitis.

• This may further lead to complications of rapid correction of sodium and hypernatremia.

• A high clinical suspicion should be exercised when met with severe asymptomatic hyponatremia. Sodium should be monitored after relieving the obstruction for spontaneous

improvement if not underlying secondary cause is identified.

We suggest evaluating for unmeasured lipids and protein to

explain the pseudohyponatremia. If these are normal, watchful

waiting after relieving the obstruction should be exercised. • Further studies are required to evaluate the causality of

pseudohyponatremia in patients with obstructive jaundice.

REFERENCES

1. Igbinedion, S.O., et al., *Pseudohyponatraemia secondary to hyperlipidaemia in obstructive jaundice.* BMJ Case Rep, 2017. **2017**.

2. Adashek, M.L., et al., The Hyperlipidemia Effect: Pseudohyponatremia in Pancreatic Cancer. Am J Med, 2017. **130**(12): p. 1372-1375.

3. Ravella, S., et al., *Hyponatremia in a patient with obstructive jaundice*. Kidney Int, 2015. **88**(4): p.

4. Cangemi, D.J., S.T. Donovan, and M.M. Johnson, 62-year-old man with painless jaundice and hyponatremia. Mayo Clin Proc, 2013. 88(6): p. e49-53.

5. Sivakumar, T., et al., Multiple lipoprotein and electrolyte laboratory artifacts caused by lipoprotein X in obstructive biliary cholestasis secondary to pancreatic cancer. J Clin Lipidol, 2011. 5(4): p. 324-8. 6. le Riche, M., L.J. Burgess, and A.D. Marais, *Pseudohyponatraemia in a patient with obstructive jaundice.* Clin Chim Acta, 2006. **366**(1-2): p. 357-60.